Licence to Save: a UK Survey of Anti-VEGF Use for the Eye in 2015

Overview

Journal Eye (Lond)

Specialty Ophthalmology

Date 2016 Aug 13

PMID 27518544

Citations 10

Authors

A K Shalaby

K Lewis

K Bush

P R Meredith

S Di Simplicio

A J Lockwood

Affiliations

Soon will be listed here.

Citing Articles

Anti-vascular endothelial growth factor biosimilars for neovascular age-related macular degeneration.

Sunaga T, Maeda M, Saulle R, Ng S, Sato M, Hasegawa T Cochrane Database Syst Rev. 2024; 6:CD015804.

PMID: 38829176 PMC: 11146280. DOI: 10.1002/14651858.CD015804.pub2.

The disparity between funding for eye research vs. the high cost of sight-loss in the UK.

Dewing J, Lotery A, Ratnayaka J Eye (Lond). 2022; 37(4):584-586.

PMID: 36167984 PMC: 9998460. DOI: 10.1038/s41433-022-02228-7.

Protein and polypeptide mediated delivery to the eye.

Attia S, MacKay J Adv Drug Deliv Rev. 2022; 188:114441.

PMID: 35817213 PMC: 10049092. DOI: 10.1016/j.addr.2022.114441.

Harnessing the Neuroprotective Behaviors of Müller Glia for Retinal Repair.

Pena J, Vazquez M Front Biosci (Landmark Ed). 2022; 27(6):169.

PMID: 35748245 PMC: 9639582. DOI: 10.31083/j.fbl2706169.

Anti-vascular endothelial growth factor in neovascular age-related macular degeneration - a systematic review of the impact of anti-VEGF on patient outcomes and healthcare systems.

Finger R, Daien V, Eldem B, Talks J, Korobelnik J, Mitchell P BMC Ophthalmol. 2020; 20(1):294.

PMID: 32680477 PMC: 7368708. DOI: 10.1186/s12886-020-01554-2.

References

Collier J . Paediatric prescribing: using unlicensed drugs and medicines outside their licensed indications. Br J Clin Pharmacol. 1999; 48(1):5-8. PMC: 2014867. DOI: 10.1046/j.1365-2125.1999.00983.x. View

Moja L, Lucenteforte E, Kwag K, Bertele V, Campomori A, Chakravarthy U . Systemic safety of bevacizumab versus ranibizumab for neovascular age-related macular degeneration. Cochrane Database Syst Rev. 2014; (9):CD011230. PMC: 4262120. DOI: 10.1002/14651858.CD011230.pub2. View

Virgili G, Parravano M, Menchini F, Evans J . Anti-vascular endothelial growth factor for diabetic macular oedema. Cochrane Database Syst Rev. 2014; (10):CD007419. DOI: 10.1002/14651858.CD007419.pub4. View

Martin D, Maguire M, Ying G, Grunwald J, Fine S, Jaffe G . Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med. 2011; 364(20):1897-908. PMC: 3157322. DOI: 10.1056/NEJMoa1102673. View

Rofagha S, Bhisitkul R, Boyer D, Sadda S, Zhang K . Seven-year outcomes in ranibizumab-treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN-UP). Ophthalmology. 2013; 120(11):2292-9. DOI: 10.1016/j.ophtha.2013.03.046. View

Dakin H, Wordsworth S, Rogers C, Abangma G, Raftery J, Harding S . Cost-effectiveness of ranibizumab and bevacizumab for age-related macular degeneration: 2-year findings from the IVAN randomised trial. BMJ Open. 2014; 4(7):e005094. PMC: 4120317. DOI: 10.1136/bmjopen-2014-005094. View

Chakravarthy U, Harding S, Rogers C, Downes S, Lotery A, Culliford L . Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial. Lancet. 2013; 382(9900):1258-67. DOI: 10.1016/S0140-6736(13)61501-9. View

Curtis L, Hammill B, Qualls L, DiMartino L, Wang F, Schulman K . Treatment patterns for neovascular age-related macular degeneration: analysis of 284 380 medicare beneficiaries. Am J Ophthalmol. 2012; 153(6):1116-24.e1. DOI: 10.1016/j.ajo.2011.11.032. View

Lock D . Avastin and Lucentis: a guide through the legal maze. BMJ. 2015; 350:h1377. DOI: 10.1136/bmj.h1377. View

10.

Schauwvlieghe A, Dijkman G, Hooymans J, Verbraak F, Hoyng C, Dijkgraaf M . Comparing the effectiveness and costs of Bevacizumab to Ranibizumab in patients with Diabetic Macular Edema: a randomized clinical trial (the BRDME study). BMC Ophthalmol. 2015; 15:71. PMC: 4491889. DOI: 10.1186/s12886-015-0043-x. View

11.

De Rosa M, Messori A . The safety of bevacizumab and ranibizumab in clinical studies. Int Ophthalmol. 2015; 35(2):157-8. DOI: 10.1007/s10792-015-0043-0. View

12.

Lushchyk T, Amarakoon S, Martinez-Ciriano J, van den Born L, Baarsma G, Missotten T . Bevacizumab in age-related macular degeneration: a randomized controlled trial on the effect of injections every 4 weeks, 6 weeks and 8 weeks. Acta Ophthalmol. 2013; 91(6):e456-61. DOI: 10.1111/aos.12119. View